2 results
Approved WMOCompleted
Primary Objective• For Arms A, B, and C: Determine the overall response rate (RR) of EZN-2208 for two distinct cohorts of patients with mCRC- Patients with mutated K-RAS tumors (Arm A)- Patients with wild-type K-RAS tumors (Arms B and C)• For Arms B…
Approved WMOCompleted
To assess safety, tolerability and pharmacokinetics of a single subcutaneous administration of HPV-NIRD1.